Tagrisso causes complaints over issue biopsy
AstraZeneca Korea mentioned about the fact the Tagrisso’s(generic name: osimertinib) health insurance benefits will only be accepted only if a tissue biopsy is positive.
Tagrisso is a novel drug which overcame EGFR-targeted therapies’ resistance for the world’s first time in the non-small cell l...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.